Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Drops By 99.1%

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 95,505 shares, a decrease of 99.1% from the August 15th total of 10,331,073 shares. Currently, 8.8% of the shares of the stock are sold short. Based on an average trading volume of 71,248 shares, the short-interest ratio is presently 1.3 days.

Liminatus Pharma Price Performance

NASDAQ LIMN opened at $3.47 on Friday. The company’s 50 day simple moving average is $5.28 and its 200 day simple moving average is $7.85. Liminatus Pharma has a 12 month low of $3.42 and a 12 month high of $141.50. The company has a market capitalization of $4.65 million, a P/E ratio of -0.15 and a beta of 5.30.

Liminatus Pharma (NASDAQ:LIMN) last issued its earnings results on Friday, August 14th. The company reported ($1.50) earnings per share for the quarter.

Wall Street Analyst Weigh In

LIMN has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Liminatus Pharma to a “strong sell” rating in a research note on Saturday, August 22nd. Weiss Ratings downgraded Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Liminatus Pharma has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.